Elze R. Timmers

Dr. Elze R. Timmers


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ETElze R. Timmers
Elze R. Timmers
MSMarenka Smit
Marenka Smit
AKAnouk Kuiper
Anouk Kuiper
ABAnna L. Bartels
Anna L. Bartels
SVSterre van der Veen
Sterre van der Veen
MTMarina Tijssen
Marina Tijssen

1 December 2017 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
ETElze R. Timmers
Elze R. Timmers
AKA. Kuiper
A. Kuiper
MSM. Smit
M. Smit
ABA.L. Bartels
A.L. Bartels
DKDaan Kamphuis
Daan Kamphuis
MTMarina Tijssen
Marina Tijssen

1 October 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
ETElze R. Timmers
Elze R. Timmers
MFMartijn van Faassen
Martijn van Faassen
MSMarenka Smit
Marenka Smit
AKAnouk Kuiper
Anouk Kuiper
IHIngrid H. Hof
Ingrid H. Hof
TKTom J. de Koning
Tom J. de Koning
In dystonia, dopaminergic alterations are considered to be responsible for the motor symptoms. Recent attention for the highly prevalent non-motor symptoms suggest also a role for serotonin in the pathophysiology. In this study we investigated the dopaminergic, serotonergic and noradrenergic metabolism in blood samples of dystonia patients and its relation with (non-)motor manifestations. Concentrations of metabolites of dopaminergic, serotonergic and noradrenergic pathways were measured in platelet-rich plasma in 41 myoclonus-dystonia (M-D), 25 dopa-responsive dystonia (DRD), 50 cervical dystonia (CD) patients and 55 healthy individuals. (Non-)motor symptoms were assessed using validated instruments, and correlated with concentrations of metabolites. A significantly higher concentration of 3-methoxytyramine (0.03 vs. 0.02 nmol/L, p < 0.01), a metabolite of dopamine, and a reduced concentration of tryptophan (50 vs. 53 μmol/L, p = 0.03), the precursor of serotonin was found in dystonia patients compared to controls. The dopamine/levodopa ratio was higher in CD patients compared to other dystonia groups (p < 0.01). Surprisingly, relatively high concentrations of levodopa were found in the untreated DRD patients. Low concentrations of levodopa were associated with severity of dystonia (rs = -0.3, p < 0.01), depression (rs = -0.3, p < 0.01) and fatigue (rs = -0.2, p = 0.04). This study shows alterations in the dopaminergic and serotonergic metabolism of patients with dystonia, with dystonia subtype specific changes. Low concentrations of levodopa, but not of serotonergic metabolites, were associated with both motor and non-motor symptoms. Further insight into the dopaminergic and serotonergic systems in dystonia with a special attention to the kinetics of enzymes involved in these pathways, might lead to better treatment options.

Verified
Journal Article
Open access
PDF file
ETElze R. Timmers
Elze R. Timmers
JSJohann Swarte
Johann Swarte
RGR. Gacesa
R. Gacesa
JBJohannes R. Björk
Johannes R. Björk
RWRinse K. Weersma
Rinse K. Weersma
Klary E Niezen-KoningKlary E Niezen-Koning
Klary E Niezen-Koning
Dystonia is a movement disorder in which patients have involuntary abnormal movements or postures. Non-motor symptoms, such as psychiatric symptoms, sleep problems and fatigue, are common. We hypothesise that the gut microbiome might play a role in the pathophysiology of the (non-)motor symptoms in dystonia via the gut–brain axis. This exploratory study investigates the composition of the gut microbiome in dystonia patients compared to healthy controls. Furthermore, the abundance of neuro-active metabolic pathways, which might be implicated in the (non-)motor symptoms, was investigated. We performed both metagenomic and 16S rRNA sequencing on the stool samples of three subtypes of dystonia (27 cervical dystonia, 20 dopa-responsive dystonia and 24 myoclonus-dystonia patients) and 25 controls. While microbiome alpha and beta diversity was not different between dystonia patients and controls, dystonia patients had higher abundances of Ruminococcus torques and Dorea formicigenerans, and a lower abundance of Butyrivibrio crossotus compared to controls. For those with dystonia, non-motor symptoms and the levels of neurotransmitters in plasma explained the variance in the gut microbiome composition. Several neuro-active metabolic pathways, especially tryptophan degradation, were less abundant in the dystonia patients compared to controls. This suggest that the gut–brain axis might be involved in the pathophysiology of dystonia. Further studies are necessary to confirm our preliminary findings.

11 December 2022 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
ETElze R. Timmers
Elze R. Timmers
TPTorsten Plösch
Torsten Plösch
MSMarenka Smit
Marenka Smit
IHIngrid H. Hof
Ingrid H. Hof
RVRikst Nynke Verkaik-Schakel
Rikst Nynke Verkaik-Schakel
KNKlary E. Niezen-Koning
Klary E. Niezen-Koning
Background: Dystonia is a rare movement disorder, in which patients suffer from involuntary twisting movements or abnormal posturing. Next to these motor symptoms, patients have a high prevalence of psychiatric comorbidity, suggesting a role for serotonin in its pathophysiology. This study investigates the percentage of DNA methylation of the gene encoding for the serotonin reuptake transporter (SLC6A4) in dystonia patients and the associations between methylation levels and presence and severity of psychiatric symptoms. Methods: Patients with cervical dystonia (n = 49), myoclonus dystonia (n = 41) and dopa-responsive dystonia (DRD) (n = 27) and a group of healthy controls (n = 56) were included. Psychiatric comorbidity was evaluated with validated questionnaires. Methylation levels of 20 CpG sites situated 69 to 213 base pairs upstream of the start codon of SLC6A4 were investigated. Methylation in dystonia patients was compared to healthy controls, correcting for age, and correlated with psychiatric comorbidity. Results: Bootstrapped quantile regression analysis showed that being a dystonia patient compared to a healthy control significantly explains the methylation level at two CpG sites (CpG 24: pseudo-R2 = 0.05, p = 0.04, CpG 32: pseudo-R2 = 0.14, p = 0.03). Subgroup analysis revealed that being a DRD patient significantly explained a part of the variance of methylation levels at two CpG sites (CpG 21: pseudo-R2 = 0.03, p = 0.00, CpG 24: pseudo-R2 = 0.06, p = 0.03). Regression analysis showed that methylation level at CpG 38 significantly explained a small proportion of the variance of severity score for anxiety (R2 = 0.07, p = 0.04) and having a diagnosis of depression (Nagelkerke R2: 0.11, p = 0.00). Genotype of the 5-HTTLPR polymorphism had no additional effect on these associations. Conclusions: This study showed an association between percentage of methylation at several specific sites of the promoter region of SLCA64 and (dopa-responsive) dystonia patients compared to healthy controls. Furthermore, methylation levels were associated with severity of anxiety and presence of a depressive disorder in the dystonia group. This study suggests alterations in the serotonergic metabolism in dystonia patients, and its relation with the non-motor symptoms.

15 March 2025 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
MVMaría I. Vanegas
María I. Vanegas
AMAnna Marcé-Grau
Anna Marcé-Grau
ACAna Cazurro‐Gutiérrez
Ana Cazurro‐Gutiérrez
FHFeline Hamami
Feline Hamami
ETElze R. Timmers
Elze R. Timmers
BPBelén Pérez‐Dueñas
Belén Pérez‐Dueñas